COMFORT-I Phase III Trial of the Benefit of Ruxolitinib versus Placebo on Spleen Volume Reduction and Symptom Improvement


COMFORT-I Phase III Trial of the Benefit of Ruxolitinib versus Placebo on Spleen Volume Reduction and Symptom Improvement
Slides from a presentation at ASH 2011 and transcribed comments from recent interviews with Hagop M Kantarjian, MD (1/13/12) and Srdan Verstovsek, MD, PhD (1/25/12)

Verstovsek S et al. Consistent benefit of ruxolitinib over placebo in spleen volume reduction and symptom improvement across subgroups and overall survival advantage: Results from COMFORT-I. Proc ASH 2011;Abstract 278.

Dr Kantarjian is Chairman and Professor in the Leukemia Department at The University of Texas MD Anderson Cancer Center in Houston, Texas.

Dr Verstovsek is Associate Professor, Chief of the Section of Myeloproliferative Neoplasms and Director of the Clinical Research Center for Myeloproliferative Neoplasms at The University of Texas MD Anderson Cancer Center in Houston, Texas.